Medication Withdrawal With Normal or Near-normal Histology in Ulcerative Colitis is Associated With Clinical Relapse
Seth R Shaffer1,2, Jenny Chu3, Amal Algarni3
1Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences.
Goals:
We sought to understand the clinical course and risk of dysplasia in persons with UC who achieve near or complete normalization of histology.
Background:
Histologic remission and normalization in ulcerative colitis (UC) is associated with improved clinical outcomes. We sought to understand the clinical course and risk of dysplasia in persons with UC who achieve near or complete normalization of histology.
Study:
We performed a retrospective single-centred study of persons with UC who were in endoscopic remission with normal histology. Pathology slides were reread by a gastrointestinal-expert pathologist and both right and left colon were scored using the Geboes score. The primary outcome was time to clinical relapse, with secondary outcomes including episodes of dysplasia and colectomy.
Results:
Seventy-eight persons had normal histology reported, although only 2 had completely normal histology on expert review. Approximately one-fifth of persons developed a clinical relapse at a mean of 4.7 years. Neither right nor left-sided colon histology was predictive of future clinical relapse. Forty-three percent of those who withdrew their IBD-therapy had a future clinical relapse, and were more likely to relapse than those who did not withdraw therapy (HR: 4.89, 95% CI: 1.32-18.08). There were zero episodes of dysplasia in follow-up, and 2 persons who relapsed ended up receiving a colectomy.
Conclusions:
Persons with UC who achieve normal or near-normal histology have moderate rates of clinical relapse. Physicians should be cautious when considering withdrawing IBD-therapy as this was associated with an increased risk of clinical relapse.
More Related Videos
09:11Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
Published on: February 14, 2021
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Related Concept Videos
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...